BMS-754807

Catalog No.S1124

BMS-754807 Chemical Structure

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Size Price Stock Quantity  
USD 180 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 6 Publications

1 Customer Review

  • Clin Cancer Res 2013 19(11), 2984-94. BMS-754807 purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.
Features Muti-inhibitor of the IGR-1R/IR family.
Targets
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
1.7 nM 1.8 nM 4.1 nM 5.6 nM 7.4 nM
In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). [1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. [2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGF-Sal NIHqSIxMcW6jc3WgZZN{[Xl? MmfQbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCLR1[tNXIhMEmFNUCgQUAyO26PKTDhcoQhfGinIHTve45{fHKnYX2geIFz\2W2czDBb5QhMEmFNUCgQUAzOm6PKTDhcoQhVUGSSzCoTWM2OCB;IEGzcm0q M{TSPFE6Pzd6MEK0
IGF-Sal M135U2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXj3W3E2UUN3ME23JI5O M3nDPFE6Pzd6MEK0
CCRF-CEM (ALL) MmS4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoXSglUh|ryP NHj4e5NFVVOR NXfwfY9GUUN3ME2xMlI{QSEQvF2= MkXqNVk6QTZ{N{K=
PC3 MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIjYeWt,PSEQvF2= NHXHSo9FVVOR NYP4VFhuUUN3ME2wMlk3PSEQvF2= M4r5e|E6QTl4Mkey
JD M3\memdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Ml;3glUh|ryP MXzEUXNQ M3\YNGlEPTB;MD6zPVEh|ryP MV[xPVk6PjJ5Mh?=
DU145 M4LSeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUj+OUDPxE1? MoDHSG1UVw>? NYfjXZpHUUN3ME2xMlQ3PSEQvF2= NIXBOIsyQTl7NkK3Ni=>
KAG M4X3Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2DhNJ42KM7:TR?= NGLBdY9FVVOR MVjJR|UxRTFwNk[1JO69VQ>? MoHuNVk6QTZ{N{K=
K-562 (CML) MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1TpW542KM7:TR?= Ml;aSG1UVw>? MVrJR|UxRTJwM{CyJO69VQ>? MYSxPVk6PjJ5Mh?=
B6-P210 (Murine ALL) MmTkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NF7oVHd,PSEQvF2= NWfBNFlRTE2VTx?= MUXJR|UxRTFwMkmzJO69VQ>? MkjDNVk6QTZ{N{K=
LN CAP-FGC Ml[wS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2L4VJ42KM7:TR?= MV3EUXNQ MnPZTWM2OD1zLkSzOEDPxE1? M3zBfFE6QTl4Mkey
VW MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXf+OUDPxE1? MnXHSG1UVw>? NHviPFJKSzVyPUCuNFE6KM7:TR?= NYHSd5dDOTl7OU[yO|I>
MV411 (B Myelomonocytic) Ml;WS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4TDXJ42KM7:TR?= NUK3OIxoTE2VTx?= M{Hje2lEPTB;MD6zN{DPxE1? MUixPVk6PjJ5Mh?=
MDA-PCa-2b NHX2[GVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGj1cIF,PSEQvF2= NF\we5JFVVOR NXTLTFFrUUN3ME2wMlA6QCEQvF2= NVfNWYNTOTl7OU[yO|I>
LG MoH4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NX;RflczhjVizszN MnfqSG1UVw>? MVjJR|UxRTBwMEO4JO69VQ>? MYGxPVk6PjJ5Mh?=
RS411 (B cell precursor-ALL) MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUfN[YpwhjVizszN NWXLW4xXTE2VTx?= Mly2TWM2OD1yLkGwNkDPxE1? MnLaNVk6QTZ{N{K=
22-r-1 M3\hWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWL+OUDPxE1? NWTkeXJPTE2VTx?= NGDFR4ZKSzVyPUCuNVc2KM7:TR?= MoS0NVk6QTZ{N{K=
5838 M1HR[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFq5WYh,PSEQvF2= MWXEUXNQ NVvXZmpiUUN3ME2wMlA{PCEQvF2= NFHibogyQTl7NkK3Ni=>
P388 (Murine) MVLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVj+OUDPxE1? MXLEUXNQ MYfJR|UxRTRwMkeg{txO NV7ufZJWOTl7OU[yO|I>
A2780/S M4XiTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUT0UFlqhjVizszN MWrEUXNQ M{L4fmlEPTB;MD6xNlIh|ryP NWS5fmpROTl7OU[yO|I>
RDES NX73O5ZPT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX3+OUDPxE1? MWjEUXNQ NGDufVBKSzVyPUCuNFEzKM7:TR?= M{fWNVE6QTl4Mkey
B6-T315I (Murine B-ALL) MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXi2bpJOhjVizszN MXPEUXNQ NUXseGl3UUN3ME2yMlg{KM7:TR?= NVrPPVI3OTl7OU[yO|I>
TOV 112D NEHGZYZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mn3XglUh|ryP MkDySG1UVw>? M{nhTGlEPTB;Mj6xOFYh|ryP NH65[2kyQTl7NkK3Ni=>
TC32 MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFH2[VN,PSEQvF2= M1\hOWROW09? NV;FUo83UUN3ME2wMlAxQCEQvF2= MUKxPVk6PjJ5Mh?=
HL60 (acute myelocytic) MnGzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXz+OUDPxE1? M1i4WGROW09? MXjJR|UxRTBwMUKg{txO MVixPVk6PjJ5Mh?=
TOV 21G NUS5N3luT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFnidZV,PSEQvF2= MYrEUXNQ NH7H[5hKSzVyPUSuNlc6KM7:TR?= Mn7pNVk6QTZ{N{K=
TC71 NX3STYdtT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NIG3epF,PSEQvF2= NU\rSFRlTE2VTx?= NHLLWHZKSzVyPUCuNFE1KM7:TR?= NHq3N|cyQTl7NkK3Ni=>
HPN-ALL (T-cell) M2f2Omdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXH+OUDPxE1? M4f1eWROW09? NYrve|BbUUN3ME2wMlUzKM7:TR?= MmPNNVk6QTZ{N{K=
A2780R M13PcGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NF3rVI9,PSEQvF2= MnzNSG1UVw>? M1K0bGlEPTB;MT61OlQh|ryP MmjkNVk6QTZ{N{K=
Rh1 M17Fdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFqyV2F,PSEQvF2= NF;tdFhFVVOR NH3IOolKSzVyPUCuNFI4KM7:TR?= MlTJNVk6QTZ{N{K=
Kasumi-1 (acute myeloid) NFf4[lZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGHLU5d,PSEQvF2= NHzKc|lFVVOR MlTKTWM2OD1yLkG2JO69VQ>? MUGxPVk6PjJ5Mh?=
sk-ov-3 Mnu3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mo\3glUh|ryP NH\5fIZFVVOR NYPLWXhlUUN3ME21MlEh|ryP NXnZNWRNOTl7OU[yO|I>
ME MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnLtglUh|ryP MULEUXNQ M{DNbmlEPTB;MD6wNVUh|ryP MX6xPVk6PjJ5Mh?=
L1210 (Murine lymphocytic) NF[zdotIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmPZglUh|ryP MVHEUXNQ NWi2T4t{UUN3ME2yMlM6KM7:TR?= MXKxPVk6PjJ5Mh?=
sw-626 Ml72S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1jlbZ42KM7:TR?= NYL6V|k3TE2VTx?= MXjJR|UxRTJwM{C2JO69VQ>? Mn7FNVk6QTZ{N{K=
CTR NWTRTGZxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NI\mNXh,PSEQvF2= MVPEUXNQ NFXpVllKSzVyPUCuNlU{KM7:TR?= NH35OZEyQTl7NkK3Ni=>
ML2 (Myelomonocytic) MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1HkT542KM7:TR?= MlnpSG1UVw>? Ml\2TWM2OD1yLkC5JO69VQ>? NIXJXZMyQTl7NkK3Ni=>
ovcar-3 NGLtSWdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHm1UlB,PSEQvF2= NFPDfY1FVVOR MVPJR|UxRTVizszN NGXtXY0yQTl7NkK3Ni=>
Rh36 NFPIdFBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWT+OUDPxE1? NV3tdmJ2TE2VTx?= NGn2cpNKSzVyPUGuOFMzKM7:TR?= NEDudFUyQTl7NkK3Ni=>
MOLM-13 (acute myeloid) NVPXe4I3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{nTUZ42KM7:TR?= NX\KWmRJTE2VTx?= MYjJR|UxRTBwNEKg{txO MkCwNVk6QTZ{N{K=
ovcar-4 M1jY[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVP2bWI1hjVizszN NWW5b3Y1TE2VTx?= MoK1TWM2OD1zIN88US=> M{LSS|E6QTl4Mkey
Rh41 NVzEcJNRT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2nxOZ42KM7:TR?= NXXDU3QzTE2VTx?= NIf3RZJKSzVyPUCuNFA2KM7:TR?= Ml\GNVk6QTZ{N{K=
Mutz 2 (acute myeloid) NVHRRZlST3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUX+OUDPxE1? NVLaeYhETE2VTx?= Mo\JTWM2OD1zLkG1JO69VQ>? MmrCNVk6QTZ{N{K=
ovcar-5 MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnXUglUh|ryP MYrEUXNQ M3PYNWlEPTB;MD6wOUDPxE1? NWDjR5RkOTl7OU[yO|I>
RD1 NY\vXoZHT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnTBglUh|ryP M3X1UmROW09? NXnR[XE2UUN3ME2wMlA3QCEQvF2= M3qx[VE6QTl4Mkey
OCI-AML 2 (acute myeloid) NWHjbm5lT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{HqeZ42KM7:TR?= MX3EUXNQ NFTxNG1KSzVyPUOuN|Mh|ryP NXfpZYNuOTl7OU[yO|I>
786-O NUHF[Zl7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX3+OUDPxE1? NHXWdGdFVVOR NVHW[pZTUUN3ME2xMlY1PyEQvF2= Mlm1NVk6QTZ{N{K=
A673 NYLNRVAxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYfwfIJKhjVizszN MXvEUXNQ M4jXOmlEPTB;MD60NFgh|ryP MXuxPVk6PjJ5Mh?=
TALL-1 (T-cell) M2XueWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnLiglUh|ryP MnHwSG1UVw>? MV\JR|UxRTFwMkig{txO NYDkfnJpOTl7OU[yO|I>
151-B M2TnWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFSybFd,PSEQvF2= MnvOSG1UVw>? NWPV[2hHUUN3ME2yMlY4KM7:TR?= MkDuNVk6QTZ{N{K=
PFSK-1 NWX5OIVNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUX+OUDPxE1? M3X6OWROW09? NF7iVo5KSzVyPUCuNVMzKM7:TR?= MYCxPVk6PjJ5Mh?=
THP-1 MkHuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGXCbIZ,PSEQvF2= M3zKV2ROW09? NGDMPJpKSzVyPU[uOVgh|ryP MoD4NVk6QTZ{N{K=
HEK293 MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NV3KVGdohjVizszN MUXEUXNQ NWq3S4JrUUN3ME2wMlkyPSEQvF2= NHGwT3kyQTl7NkK3Ni=>
DAOY MkG3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVXKPVVZhjVizszN NITibXBFVVOR NHq4emNKSzVyPUGuPVc6KM7:TR?= NYXScFVSOTl7OU[yO|I>
SET2 NHj1UJJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYX4VnR2hjVizszN NF3Y[|JFVVOR MVnJR|UxRTBwMkm4JO69VQ>? Ml2yNVk6QTZ{N{K=
HTB-46 NEjQ[4lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXz+OUDPxE1? M4fDPWROW09? MWjJR|UxRTVwMkWg{txO MYSxPVk6PjJ5Mh?=
SK-NAS MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUf+OUDPxE1? Mnz2SG1UVw>? M4Htc2lEPTB;MD60PVch|ryP NUK0fZhNOTl7OU[yO|I>
CTLL2 MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M17EVp42KM7:TR?= MnW3SG1UVw>? MXnJR|UxRjFwMECg{txO NGOyS3kyQTl7NkK3Ni=>
HTB-47 MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVi2XWRWhjVizszN Ml:4SG1UVw>? NUXQ[Xo{UUN3ME2yMlA2PiEQvF2= M1GxXFE6QTl4Mkey
LAN-1 MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVT+OUDPxE1? NIjvOnFFVVOR NEfTc|VKSzVyPUCuNFQh|ryP MlL6NVk6QTZ{N{K=
ST486 MmTWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NH3XVop,PSEQvF2= NFrDWZpFVVOR M3\KRWlEPTB;MT6xPUDPxE1? NGrXXGsyQTl7NkK3Ni=>
HS766T Mk[0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3PET542KM7:TR?= NYnO[IgyTE2VTx?= NF\rUGNKSzVyPUKuNFAyKM7:TR?= M{fFc|E6QTl4Mkey
IMR-32 MnL2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MkH5glUh|ryP NHPTe5lFVVOR M{XFfWlEPTB;MD6yOlEh|ryP M4jWNVE6QTl4Mkey
Daudi (Burkitt's) NFzzUYZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NF;XOpN,PSEQvF2= NH3pRXlFVVOR NUDuVXg3UUN3ME2yMlY{PyEQvF2= MojONVk6QTZ{N{K=
Aspc-1 NH\iTllIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Ml\0glUh|ryP MUHEUXNQ NHWwOWZKSzVyPUCuN|c6KM7:TR?= M4fq[VE6QTl4Mkey
SK-NSH NEfWTJpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3PIOp42KM7:TR?= MkPiSG1UVw>? NGTDOJBKSzVyPUCuNVM6KM7:TR?= MVqxPVk6PjJ5Mh?=
MEC-1 (Chronic B cell) M3\Ucmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVHwbJljhjVizszN MVfEUXNQ NWrDUo1pUUN3ME2yMlY{PyEQvF2= M{jHPVE6QTl4Mkey
Capan-2 MlTtS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFfCeVd,PSEQvF2= MkiwSG1UVw>? M3:0PGlEPTB;MT63O|Qh|ryP MlPwNVk6QTZ{N{K=
SHSY5Y NIrSd41Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWj4O5prhjVizszN M1u0NGROW09? NXjwbmNsUUN3ME2wMlExPiEQvF2= NV34TItVOTl7OU[yO|I>
U937 (Histioocytic) NITlbZZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoH0glUh|ryP MV7EUXNQ MXPJR|UxRjVwMECg{txO MVqxPVk6PjJ5Mh?=
Bxpc-1 NUT6UFd4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NIriZpV,PSEQvF2= MWHEUXNQ MUHJR|UxRTFwOUK0JO69VQ>? M2fhN|E6QTl4Mkey
Bxpc-3 MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MkfpglUh|ryP MYDEUXNQ MXzJR|UxRjVwMECg{txO MmrxNVk6QTZ{N{K=
HTB-92 MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnrDglUh|ryP M2PSbGROW09? NHHufYlKSzVyPUGuNFIh|ryP MYOxPVk6PjJ5Mh?=
OCI-LY10 (B-cell) NILH[GFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NEPyUm9,PSEQvF2= MVjEUXNQ NHLLZ4hKSzVyPUCuOFUh|ryP Ml;CNVk6QTZ{N{K=
PANC-1 NWTrV|NMT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEfTRZR,PSEQvF2= Mn7JSG1UVw>? M3LEOWlEPTB-NT6wNEDPxE1? NYj6VnVqOTl7OU[yO|I>
To184.T MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIm2UVV,PSEQvF2= M{e0Z2ROW09? MVzJR|UxRTBwNE[5JO69VQ>? MlfYNVk6QTZ{N{K=
OCI-LY19 (B-cell) MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUH+OUDPxE1? MYfEUXNQ MVzJR|UxRTBwNDFOwG0> MYCxPVk6PjJ5Mh?=
PANC-1 BM NHrIV21Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{jNTp42KM7:TR?= M3\xWWROW09? NFrvR4xKSzVyPkWuNFAh|ryP M4XRRlE6QTl4Mkey
SA-4 NW\lVW1GT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFjFNmJ,PSEQvF2= MUfEUXNQ MXjJR|UxRTFwM{CxJO69VQ>? MorqNVk6QTZ{N{K=
RPMI 8226 NIPSZnRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4DvOp42KM7:TR?= M1HDS2ROW09? MUfJR|UxRTFwMkmzJO69VQ>? M2HxWVE6QTl4Mkey
HPAF-II MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYL+OUDPxE1? MXrEUXNQ M2Kw[mlEPTB;MD62OFQh|ryP MYWxPVk6PjJ5Mh?=
SHP-77 MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWXGWVdVhjVizszN NVvZc3NLTE2VTx?= NVy1NWtrUUN3ME2xMlg5QCEQvF2= M2WxdlE6QTl4Mkey
U266 B1 MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NULaW2c2hjVizszN MVjEUXNQ MlnjTWM2OD1zLk[2PUDPxE1? NHPhfIwyQTl7NkK3Ni=>
Hs700t NUDTZmNqT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGryRWt,PSEQvF2= M4XVVWROW09? NEHiOXNKSzVyPUCuNlMyKM7:TR?= NV;wdIdXOTl7OU[yO|I>
NCI-446 M2DaSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1fYSZ42KM7:TR?= NXnnOmMzTE2VTx?= M3fEZWlEPTB;MT6xOVQh|ryP M1;ZVFE6QTl4Mkey
H929 M{DGNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHzZXFl,PSEQvF2= MoHYSG1UVw>? MnzJTWM2OD1yLkCxOEDPxE1? NE\3PJIyQTl7NkK3Ni=>
PL45 M{nz[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVn+OUDPxE1? MVTEUXNQ MV3JR|UxRTJwMkW1JO69VQ>? M1nMVFE6QTl4Mkey
NCI-H383 NHP0RWNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NV;OOYtwhjVizszN NYXyUHp7TE2VTx?= MmXkTWM2OD53LkCwJO69VQ>? NEDWPWEyQTl7NkK3Ni=>
JJN3 NH\3UVJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1zQep42KM7:TR?= NU[yRpVTTE2VTx?= M2LHNGlEPTB;Mj60N|Mh|ryP MoPRNVk6QTZ{N{K=
SU.86.86 MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoGxglUh|ryP NWLCe2hXTE2VTx?= MoHWTWM2OD1{Lk[3NkDPxE1? M{XGZlE6QTl4Mkey
H1299 NH;NXYFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXn+OUDPxE1? MmDISG1UVw>? NW[4bld5UUN3ME61MlAxKM7:TR?= MoLlNVk6QTZ{N{K=
MDA-MB-468 NULyXJM3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYTlOppwhjVizszN M1vud2ROW09? NFrNNolKSzVyPUCuOVA1KM7:TR?= NY[2eVR1OTl7OU[yO|I>
SW1990 MnjaS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NInoXoF,PSEQvF2= MUfEUXNQ M4S4XGlEPTB;MD64NlYh|ryP MX2xPVk6PjJ5Mh?=
Calu-6 MkDRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmnhglUh|ryP MlzySG1UVw>? M3O3OWlEPTB-NT6wNEDPxE1? Mlv3NVk6QTZ{N{K=
MDA-MB-231 NHL6TJJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3nmS542KM7:TR?= M2[zdGROW09? NGe0R25KSzVyPUGuOlQ5KM7:TR?= M1n4OFE6QTl4Mkey
SW-684 NFi5[npIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NW\oU4Q{hjVizszN NWfUV3JiTE2VTx?= NVXKXHJbUUN3ME61MlAxKM7:TR?= NFz0bnoyQTl7NkK3Ni=>
H209 M2XDbmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4ji[p42KM7:TR?= NHnM[lZFVVOR NW\GWnkxUUN3ME2xMlE6OyEQvF2= M1j4RVE6QTl4Mkey
MDA-MB-231T M{jNR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYP+OUDPxE1? NXvnN2hZTE2VTx?= M4PLOWlEPTB-NT6wNEDPxE1? M4f1cFE6QTl4Mkey
HT1080/S MlPMS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHHGWpZ,PSEQvF2= NGqyS4pFVVOR MlfOTWM2OD1yLkWzNUDPxE1? M4fDXFE6QTl4Mkey
H526 0.044 M3\6eWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWna[ZJbhjVizszN NU\DcJJtTE2VTx?= NVXEdWEyUUN3ME2wMlA1PCEQvF2= MWexPVk6PjJ5Mh?=
DU4475 2.431 NG\wOZVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2f1dZ42KM7:TR?= M13zcGROW09? Mk\hTWM2OD1{LkSzNUDPxE1? M2DWfFE6QTl4Mkey
HCT116 NVHRXnpnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MW\+OUDPxE1? M{H6fWROW09? MlfpTWM2OD1yLki1NkDPxE1? M1T1SlE6QTl4Mkey
M109 NFT0WYhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlLDglUh|ryP NUTkfHRXTE2VTx?= Mm\wTWM2OD1zLkC1OUDPxE1? NX;lbnFXOTl7OU[yO|I>
BT549 M2[3Omdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MojTglUh|ryP NVPnb2ZKTE2VTx?= NXjWenZoUUN3ME2xMlY1PSEQvF2= NVn0cYJnOTl7OU[yO|I>
HCT116/VM46 MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MW\+OUDPxE1? NXnVdm5ETE2VTx?= NILi[JZKSzVyPUGuO|AzKM7:TR?= MlfSNVk6QTZ{N{K=
H460 NWPJWnFIT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVj+OUDPxE1? NHTtPXVFVVOR M1vpWmlEPTB;MD63PVUh|ryP NUDVVYpEOTl7OU[yO|I>
MCF-7 M{C3dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXjYU217hjVizszN NXjEXXdoTE2VTx?= NHjWfW1KSzVyPUCuNFE3KM7:TR?= Mn\mNVk6QTZ{N{K=
GEO M{nqdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWLQbW5uhjVizszN NHKy[IVFVVOR MV;JR|UxRTBwM{W2JO69VQ>? MkLDNVk6QTZ{N{K=
H441 0.646 NYDLVFR2T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnP1glUh|ryP MXLEUXNQ M2fQdWlEPTB;MD62OFYh|ryP MYKxPVk6PjJ5Mh?=
MCF-7-807R MljPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWL+OUDPxE1? Ml3DSG1UVw>? NYr4OFhqUUN3ME2wMlQ6KM7:TR?= MkmwNVk6QTZ{N{K=
Colo205 MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXLweVdrhjVizszN M3HmN2ROW09? MoDlTWM2OD1yLkGwOEDPxE1? MXixPVk6PjJ5Mh?=
H292 M1y2TWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUnKPYRPhjVizszN M2e3R2ROW09? Mk\yTWM2OD1yLke4PEDPxE1? M1nW[lE6QTl4Mkey
BT474 (S) NV;EOXR3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWXQU|JzhjVizszN M2TnWmROW09? M3nncGlEPTB;Mj60NFMh|ryP MUKxPVk6PjJ5Mh?=
HT-29 MmjZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHvlfIt,PSEQvF2= NFPYTZdFVVOR NH;FZYpKSzVyPUKuNVA{KM7:TR?= NY\nRXNMOTl7OU[yO|I>
A549 M{PBVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnrTglUh|ryP NXH6PYRpTE2VTx?= NYPlZWVIUUN3ME2wMlY4PSEQvF2= MmnlNVk6QTZ{N{K=
BT474-M1 NInmSpdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFPIeIp,PSEQvF2= M3X2[WROW09? NXLS[ZJrUUN3ME2yMlM3PSEQvF2= NHPMXWYyQTl7NkK3Ni=>
SW480 MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NU\5V5NwhjVizszN NGTFeGFFVVOR NFzFR3FKSzVyPkWuNFAh|ryP Ml7tNVk6QTZ{N{K=
L2987 NWS1c5A3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoXPglUh|ryP MlmzSG1UVw>? MV\JR|UxRTBwNESyJO69VQ>? NFrjXW0yQTl7NkK3Ni=>
AU565 M2Pmemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mln5glUh|ryP MVHEUXNQ MmPTTWM2OD12Lkm3JO69VQ>? NV\NfJQ2OTl7OU[yO|I>
SW403 MkXtS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWT+OUDPxE1? MmC0SG1UVw>? MlrJTWM2OD1yLkKyJO69VQ>? NWHlU2htOTl7OU[yO|I>
H1437 MmrNS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mm\lglUh|ryP NInMbZZFVVOR NID1SGtKSzVyPUCuOVI{KM7:TR?= NUTNWmtEOTl7OU[yO|I>
BT-20 MlXwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NV2zbHVJhjVizszN NUfic2ZyTE2VTx?= M3jCOGlEPTB;Mz61OlIh|ryP NECzVJoyQTl7NkK3Ni=>
Colo320HSR NX3KcG5ZT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mk\kglUh|ryP Mnz2SG1UVw>? MVTJR|UxRTBwMEGxJO69VQ>? M2T3c|E6QTl4Mkey
H2087 Mn36S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlvUglUh|ryP MkLhSG1UVw>? MkTVTWM2OD5zLkCwJO69VQ>? MkDINVk6QTZ{N{K=
HCC1419 M{ixVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NF3hVGZ,PSEQvF2= NGL5bo1FVVOR NHzPNZZKSzVyPUKuOVE4KM7:TR?= NGfRe28yQTl7NkK3Ni=>
WiDr NILVPHhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mm\LglUh|ryP M2fDbWROW09? MmXSTWM2OD1yLkC3OkDPxE1? M37lcVE6QTl4Mkey
H661 0.573 MnflS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIXkUJV,PSEQvF2= M{fyXmROW09? M1vQZ2lEPTB;MD61O|Mh|ryP NUPRbo9sOTl7OU[yO|I>
HCC-38 NXv0bVk4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYfHSG1nhjVizszN NYS5Z3o2TE2VTx?= MXzJR|UxRjVwMECg{txO MmrJNVk6QTZ{N{K=
LS174T NEmw[FVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHzKVHh,PSEQvF2= M{XLU2ROW09? MXrJR|UxRTBwNUO1JO69VQ>? M37jfFE6QTl4Mkey
H211 MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoSzglUh|ryP NFvQWmZFVVOR NI\5S3BKSzVyPUCuO|M{KM7:TR?= MXyxPVk6PjJ5Mh?=
HCC70 NXXrSlNXT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYr+OUDPxE1? NIPlTmtFVVOR MVrJR|UxRTFwNUWg{txO NXfBOYJ7OTl7OU[yO|I>
SW116 NXvTc4xYT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4\rN542KM7:TR?= MVnEUXNQ M3HufGlEPTB;MD6wOlch|ryP NFzndmQyQTl7NkK3Ni=>
H513 M3LJeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NIixeZN,PSEQvF2= MUHEUXNQ M2fqfGlEPTB;ND60OFgh|ryP NWnOfJhEOTl7OU[yO|I>
MDA-MB-157 MorsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVj+OUDPxE1? MVrEUXNQ NFPNdo9KSzVyPUCuNFM3KM7:TR?= NHP0OngyQTl7NkK3Ni=>
H2052 MVzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXT+OUDPxE1? MUDEUXNQ NFT3SI1KSzVyPUGuNFUh|ryP MVWxPVk6PjJ5Mh?=
MDA-MB-415 MoPlS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYX+OUDPxE1? MV3EUXNQ MoLRTWM2OD53LkCwJO69VQ>? NFGxZoYyQTl7NkK3Ni=>
DLD-1 NIjJ[HVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NETQTXd,PSEQvF2= M{PEUGROW09? NYfYd3pMUUN3ME2wMlkxQSEQvF2= MVOxPVk6PjJ5Mh?=
H2595 MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NF3WOHh,PSEQvF2= NVHWflltTE2VTx?= NGTtVXVKSzVyPUSuOFc2KM7:TR?= MmnoNVk6QTZ{N{K=
MDA-MB-435S NEjT[lZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUO3c2xJhjVizszN Mm\1SG1UVw>? Mlv5TWM2OD1zLki2PUDPxE1? M3r2Z|E6QTl4Mkey
HCT15 MkfnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYWx[49yhjVizszN Mnn6SG1UVw>? MUXJR|UxRjFwMECg{txO NIPDc5gyQTl7NkK3Ni=>
SK-Hep1 NYfXbpZYT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{T2cp42KM7:TR?= NIXZOmRFVVOR M1fae2lEPTB;MD6xOFYh|ryP MUSxPVk6PjJ5Mh?=
MDA-MB-436 NHzoT|VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXX+OUDPxE1? MmD0SG1UVw>? NHrWSIFKSzVyPUWuOVAzKM7:TR?= MYexPVk6PjJ5Mh?=
KM12C NGnmRmhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFfkU4J,PSEQvF2= MojPSG1UVw>? Mn\5TWM2OD1yLkC1OEDPxE1? MXSxPVk6PjJ5Mh?=
HEPG2 Mny4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1\Kcp42KM7:TR?= MnGzSG1UVw>? NFK2NFFKSzVyPUCuNFI2KM7:TR?= M4HMRVE6QTl4Mkey
MDA-MB-453 MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3fROp42KM7:TR?= M4n5VWROW09? NWS5fFhnUUN3ME2xMlg3QSEQvF2= MV:xPVk6PjJ5Mh?=
KM12SM MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWfCZotkhjVizszN NW\yeJc4TE2VTx?= M4rBXWlEPTB;MD6wOVkh|ryP MXKxPVk6PjJ5Mh?=
1483 MlflS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlL5glUh|ryP MVTEUXNQ MnG4TWM2OD1{LkG5JO69VQ>? Mn2xNVk6QTZ{N{K=
Hs578t NIPzbGFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NEKyWW5,PSEQvF2= NGnNRZJFVVOR NGHvPFZKSzVyPUGuNlg4KM7:TR?= NXX1TGt6OTl7OU[yO|I>
LS180 NHnxfldIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWX+OUDPxE1? M13oSmROW09? MYjJR|UxRTBwNkm2JO69VQ>? M{PLd|E6QTl4Mkey
FaDu M2j2ZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVXWRYxThjVizszN Ml3ZSG1UVw>? MlPDTWM2OD1zLkK3JO69VQ>? NYnwWpBOOTl7OU[yO|I>
ZR-75-1 MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mnz0glUh|ryP M{LNTmROW09? NH\nWnRKSzVyPUKuNFg1KM7:TR?= NYfON4loOTl7OU[yO|I>
LS513 M{PFR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NELHOIp,PSEQvF2= NIiyRZpFVVOR MWTJR|UxRTBwMUO1JO69VQ>? MXuxPVk6PjJ5Mh?=
Detroit.562 NV;hU|d7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWTnPHhWhjVizszN NIP5c2tFVVOR MXfJR|UxRTFwMUSg{txO MX[xPVk6PjJ5Mh?=
ZR-75-30 MmDBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVT+OUDPxE1? NWW0VnRmTE2VTx?= MlHDTWM2OD53LkCwJO69VQ>? NGnXPZkyQTl7NkK3Ni=>
RKO-PM M4rZVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3\nXZ42KM7:TR?= MWTEUXNQ NITjOotKSzVyPUCuNlMzKM7:TR?= NFjJPHkyQTl7NkK3Ni=>
Cal.27 NHq2ZnBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYDlUnBthjVizszN MlTkSG1UVw>? MYjJR|UxRTJizszN NV3VbZUzOTl7OU[yO|I>
KPL4 NUGzUWt3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3zhZZ42KM7:TR?= MmnXSG1UVw>? MnqwTWM2OD1zLkK1NkDPxE1? NEDRVHoyQTl7NkK3Ni=>
PKO-RM13 MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mm\mglUh|ryP M3f0VWROW09? NWGxZXhMUUN3ME2wMlQzPSEQvF2= NHTNNFIyQTl7NkK3Ni=>
HS.53.T MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2HiOZ42KM7:TR?= MVHEUXNQ NGjqS4NKSzVyPUCuO|kh|ryP MXmxPVk6PjJ5Mh?=
EMT6 MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MU\+OUDPxE1? NXnZdJBSTE2VTx?= NF36O3NKSzVyPUCuPFA3KM7:TR?= MVWxPVk6PjJ5Mh?=
SNU-C1 MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3znXJ42KM7:TR?= NHrodWpFVVOR NH;WNWFKSzVyPUCuNFA4KM7:TR?= NW\ONXNkOTl7OU[yO|I>
SQCCY1 M1PJdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4G4UZ42KM7:TR?= MkfXSG1UVw>? MmnuTWM2OD1yLke5JO69VQ>? NXTzS4pUOTl7OU[yO|I>
SW480 M3LpT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkXpglUh|ryP MmLZSG1UVw>? NGHlcnNKSzVyPUCuNFM4KM7:TR?= MV2xPVk6PjJ5Mh?=
SCC9 MoroS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIfTe3Z,PSEQvF2= M1PUb2ROW09? NVnCc5hZUUN3ME2wMlc2KM7:TR?= MnjTNVk6QTZ{N{K=
SK-LMS-1 M2rVdGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NILIcIZ,PSEQvF2= MmfpSG1UVw>? NHTqSoRKSzVyPUCuOlg4KM7:TR?= MoWxNVk6QTZ{N{K=
SCC25 M4nVUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mm\CglUh|ryP Ml;tSG1UVw>? NH3IOIZKSzVyPUCuOlgh|ryP MYGxPVk6PjJ5Mh?=
U87 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYX+OUDPxE1? MX3EUXNQ MoTOTWM2OD1yLkm1JO69VQ>? NVnQXnQ1OTl7OU[yO|I>
SCC15 MkSxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXXO[Gw{hjVizszN MYHEUXNQ NGjqfVJKSzVyPUCuOlch|ryP NYrDRnZmOTl7OU[yO|I>
T98G M{fxZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFHhTIN,PSEQvF2= NV3ZXXoyTE2VTx?= MVXJR|UxRTFwMkG4JO69VQ>? MoDtNVk6QTZ{N{K=
SCC4 MorDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXT+OUDPxE1? MXjEUXNQ NHrud2ZKSzVyPUCuOlMh|ryP NXfISHFKOTl7OU[yO|I>
U118 NV35fYh4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmPVglUh|ryP NWDjOoE4TE2VTx?= M33tfmlEPTB;MT62NVgh|ryP MXyxPVk6PjJ5Mh?=
TU167 MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIXoNYh,PSEQvF2= Mn7qSG1UVw>? NYnRVoNbUUN3ME20MlUzKM7:TR?= MoPONVk6QTZ{N{K=
NCI-H727 NWLh[nBoT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4fLTp4yOOLCit88US=> M37tZ2ROW09? MWXJR|UxRTR{ODDuUS=> NWLIVY5[OjB|OEW3OFc>
NCI-H720 MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVzO[|h4hjFy4pEK{txO MnPFSG1UVw>? NHfhXm9KSzVyPUKuPEDPxE1? M1nDfFIxOzh3N{S3
NCI-H835 M3:wN2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2DESp4yOOLCit88US=> MojlSG1UVw>? NYHWd|V{UUN3ME2xJO69VQ>? NV;HcIxsOjB|OEW3OFc>
NCI-H727 M3zGS2tqdmG|ZTDhd5NigQ>? NYDHNJhShjFy4pEK{txO NVjWcHlITE2VTx?= MVnpcohq[mm2czDjc45{fGm2dYTpeoUhUUeIMWKgZZV1d3Cqb4PwbI9zgWyjdHnvci=> NHLiboczODN6NUe0Oy=>
RD NFLoSm9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkjlglEx6oDMzszN MofhTWM2OD1zLkGyJOK2VQ>? MVyyNVI6QDd2NR?=
Rh41 M2\6Wmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVvxW2VNhjFy4pEK{txO M1y5WWlEPTB;MD6wO{DDvU1? MUKyNVI6QDd2NR?=
Rh18 MmrCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWn+NVDjiIsQvF2= M{HDdWlEPTB;ND65OkDDvU1? M1q4XFIyOjl6N{S1
Rh30 NVTtd5p4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX;+NVDjiIsQvF2= M2Hod2lEPTB;MD6xPUDDvU1? MWKyNVI6QDd2NR?=
BT-12 NX3uSGtiT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NITXfHp,OTEkgJtOwG0> MmT4TWM2OD1yLke4JOK2VQ>? M4e5eFIyOjl6N{S1
CHLA-266 NIXrNlNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{HsU54yOOLCit88US=> Mn;KTWM2OD1yLki5JOK2VQ>? MY[yNVI6QDd2NR?=
TC-71 M{fvZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4jHR54yOOLCit88US=> Mn[2TWM2OD1yLkGxJOK2VQ>? MViyNVI6QDd2NR?=
CHLA-9 Mnn4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHjnNWx,OTEkgJtOwG0> NUXWUXhuUUN3ME2wMlEzKML3TR?= M3L5eVIyOjl6N{S1
CHLA-10 M4n5dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NEj3UIF,OTEkgJtOwG0> NXvndpFsUUN3ME2wMlYzKML3TR?= NXPQdoNUOjF{OUi3OFU>
CHLA-258 M4LDSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVT+NVDjiIsQvF2= MlXmTWM2OD1yLkK3JOK2VQ>? NIPsS4wzOTJ7OEe0OS=>
GBM2 NVPMSZp[T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NE\oXol,OTEkgJtOwG0> NHzOOI9KSzVyPUGuOFchyrWP MUiyNVI6QDd2NR?=
NB-1643 NIK3dGtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NE\JSZh,OTEkgJtOwG0> MV7JR|UxRTBwMUKgxtVO M1zqdFIyOjl6N{S1
NB-EBc1 NVL6eVNYT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4j0Sp4yOOLCit88US=> MoW4TWM2OD1yLkO1JOK2VQ>? NXvyc29qOjF{OUi3OFU>
CHLA-90 MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2XYS54yOOLCit88US=> MkfFTWM2OD1yLke3JOK2VQ>? M{PKfFIyOjl6N{S1
CHLA-136 M2izc2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUfVSnE1hjFy4pEK{txO NGnDVJZKSzVyPUCuOVIhyrWP MnzmNlEzQTh5NEW=
NALM-6 M2LUcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXrJVZR4hjFy4pEK{txO NWLOeVk{UUN3ME2wMlQ6KML3TR?= NEXPOYUzOTJ7OEe0OS=>
COG-LL-317 Moq0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGTzW2h,OTEkgJtOwG0> NGTpPWxKSzVyPUGuN|ghyrWP MYGyNVI6QDd2NR?=
RS4;11 NYLtO5RZT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWfoWFJohjFy4pEK{txO MYXJR|UxRTBwM{igxtVO MUKyNVI6QDd2NR?=
MOLT-4 M3H4S2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NH\hbVl,OTEkgJtOwG0> MX\JR|UxRTBwNUOgxtVO Mor4NlEzQTh5NEW=
CCRF-CEM MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGPXZZd,OTEkgJtOwG0> M1TYcWlEPTB;MT6xN{DDvU1? NXT4N3o1OjF{OUi3OFU>
Kasumi-1 MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFTjdW1,OTEkgJtOwG0> NWTN[G1iUUN3ME2xMlIhyrWP MoLQNlEzQTh5NEW=
Karpas-299 Ml;6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4DRdp4yOOLCit88US=> MVjJR|UxRTFwNkSgxtVO MX[yNVI6QDd2NR?=
Ramos-RA1 MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFjrSYZ,OTEkgJtOwG0> NFu4[ohKSzVyPUGuN|EhyrWP MXeyNVI6QDd2NR?=
Rh30  M2DtOmZ2dmO2aX;uJIF{e2G7 M2HZV4lv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?= NIXl[pgzPTl{NUO3PC=>
Rh41 MmfXSpVv[3Srb36gZZN{[Xl? M{LKUolv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?= MUiyOVkzPTN5OB?=
RD NGrWPZlHfW6ldHnvckBie3OjeR?= NIm5S2dqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:|cHjvdplt[XSrb36= M1PKbFI2QTJ3M{e4
A549 M4fyNWtqdmG|ZTDhd5NigQ>? NITGWowxNjYkgJtOwG0> MYjEUXNQ M4fnbYlvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v NWXNNmZ6OjZ7Mki1O|g>
NCI-H358 M2jpR2tqdmG|ZTDhd5NigQ>? M4rZO|AvPeLCit88US=> Mn;oSG1UVw>? MVvpcohq[mm2czDJS2YuUVJxSWKgZYN1cX[jdHnvci=> MVmyOlkzQDV5OB?=
A549 MULGeY5kfGmxbjDhd5NigQ>? M3TxUVAvPeLCit88US=> Mn:0SG1UVw>? NHHOW2Vk[XW|ZYOgZUBkd26ldYLy[Y51KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGNVDDhcoQhTVKN NEHISYkzPjl{OEW3PC=>
NCI-H358 NWS2b2NDTnWwY4Tpc44h[XO|YYm= NFTsZpkxNjYkgJtOwG0> M2\iTGROW09? MXnjZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM MVSyOlkzQDV5OB?=
A549 NH7CeWVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2q5Wp4yOOLCit88US=> MYDEUXNQ MVzJR|UxRTBwN{[g{txO NUD0[lllOjZ7Mki1O|g>
NCI-H358 MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlLnglEx6oDMzszN Mm\jSG1UVw>? M2e4PGlEPTB;MT6wPUDPxE1? MlP2NlY6Ojh3N{i=
A549 MmjPRZBweHSxc3nzJIF{e2G7 M4f5PVAvPeLCit88US=> NELlO3dFVVOR MXvpcoR2[2W|IFHwc5B1d3Orcx?= NYfEclU3OjZ7Mki1O|g>
NCI-H358 M3:4[WFxd3C2b4Ppd{Bie3OjeR?= M3TMOlAvPeLCit88US=> NIPHc4tFVVOR MV3pcoR2[2W|IFHwc5B1d3Orcx?= NXzFR|ZkOjZ7Mki1O|g>
A549 NVrYbJZPTnWwY4Tpc44h[XO|YYm= M1\zcVAvPeLCit88US=> MVjEUXNQ MlvXdoVlfWOnczD3c5Vv\CClbH;zeZJm NHO5O|kzPjl{OEW3PC=>
NCI-H358 M{iwV2Z2dmO2aX;uJIF{e2G7 M4fM[lAvPeLCit88US=> MkPESG1UVw>? MUfy[YR2[2W|IIfveY5lKGOub4P1doU> MX[yOlkzQDV5OB?=

... Click to View More Cell Line Experimental Data

In vivo BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. [1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. [2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Kinase inhibition assays:

The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to Km ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:[1]
+ Expand
  • Cell lines: IGF-1R-Sal, RH41 and Geo cell lines
  • Concentrations: 365 nM
  • Incubation Time: 72 hours
  • Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of 3H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice
  • Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol)
  • Dosages: 150 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 92 mg/mL (199.35 mM)
Ethanol 92 mg/mL (199.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.49
Formula

C23H24FN9O

CAS No. 1001350-96-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01525823 Completed Healthy Volunteers Bristol-Myers Squibb February 2012 Phase 1
NCT01525823 Completed Healthy Volunteers Bristol-Myers Squibb February 2012 Phase 1
NCT01225172 Completed Breast Cancer Bristol-Myers Squibb|Mayo Clinic December 2010 Phase 2
NCT01225172 Completed Breast Cancer Bristol-Myers Squibb|Mayo Clinic December 2010 Phase 2
NCT00908024 Terminated Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis Bristol-Myers Squibb October 2009 Phase 1|Phase 2
NCT00908024 Terminated Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis Bristol-Myers Squibb October 2009 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Tags: buy BMS-754807 | BMS-754807 supplier | purchase BMS-754807 | BMS-754807 cost | BMS-754807 manufacturer | order BMS-754807 | BMS-754807 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID